Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 22

Sort by

Sort Order Select

Journal Articles

Tumor-Immune Architecture and the Regulation of Antigen-Specific T-Cell Infiltration in Multiple Myeloma and Premalignant Plasma Cell Disorders

Blood (2022) 140 (Supplement 1): 244–245.

https://doi.org/10.1182/blood-2022-169558

Published: 2022

Journal Articles

KarMMa-2 Cohort 2a: Efficacy and Safety of Idecabtagene Vicleucel in Clinical High-Risk Multiple Myeloma Patients with Early Relapse after Frontline Autologous Stem Cell Transplantation

Saad Usmani, Krina Patel, Parameswaran Hari, Jesus Berdeja, Melissa Alsina, Ravi Vij, Noopur Raje, Xavier Leleu, Madhav Dhodapkar, Ran Reshef, Anna Truppel-Hartmann, Debashree Basudhar, Ethan Thompson, Xirong Zheng, Revathi Ananthakrishnan, Chiara Greggio, Linda Favre-Kontula, Lars Sternas, Jesús San-Miguel

Blood (2022) 140 (Supplement 1): 875–877.

https://doi.org/10.1182/blood-2022-162469

Published: 2022

Journal Articles

KarMMa-2 Cohort 2c: Efficacy and Safety of Idecabtagene Vicleucel in Patients with Clinical High-Risk Multiple Myeloma Due to Inadequate Response to Frontline Autologous Stem Cell Transplantation

Madhav Dhodapkar, Melissa Alsina, Jesus Berdeja, Krina Patel, Ravi Vij, Xavier Leleu, Anna Truppel-Hartmann, Debashree Basudhar, Ethan Thompson, Xirong Zheng, Revathi Ananthakrishnan, Linda Favre-Kontula, Chiara Greggio, Lars Sternas, David Siegel

Blood (2022) 140 (Supplement 1): 7441–7443.

https://doi.org/10.1182/blood-2022-162615

Published: 2022

Journal Articles

Phase 1 Trial of AUC-Targeted Melphalan in Myeloma Patients Undergoing Autologous Transplant (The MyMel Study)

Karen Sweiss, Pritesh Patel, Janet Guo, Kyeongmin Kim, Kasey Hill, Nicole Abbott, Jeremy Johnson, Donald Irby, John G. Quigley, Damiano Rondelli, R Donald Harvey, Ajay K. Nooka, Madhav Dhodapkar, Jonathan L. Kaufman, Nisha S. Joseph, Sagar Lonial, Douglas W. Sborov, Mitch A Phelps, Craig C Hofmeister

Blood (2022) 140 (Supplement 1): 5988–5990.

https://doi.org/10.1182/blood-2022-170778

Published: 2022

Journal Articles

A Phase 2 Evaluation of Daratumumab-Based Induction Therapy in Multiple Myeloma Patients with Severe Renal Insufficiency

R Donald Harvey, Joseph K Franz, Nisha S. Joseph, Jonathan L. Kaufman, Elise Hitron, Hannah Collins, Catherine Braga, Ludimila Cavalcante, Kathryn T. Maples, Craig C Hofmeister, Madhav Dhodapkar, Sagar Lonial, Ajay K. Nooka

Blood (2022) 140 (Supplement 1): 12633–12634.

https://doi.org/10.1182/blood-2022-157047

Published: 2022

Journal Articles

Updated Safety and Efficacy of REGN5458, a BCMAxCD3 Bispecific Antibody, Treatment for Relapsed/Refractory Multiple Myeloma: A Phase 1/2 First-in-Human Study

Blood (2022) 140 (Supplement 1): 10140–10141.

https://doi.org/10.1182/blood-2022-159969

Published: 2022

Journal Articles

African American Race As a Risk Factor for Developing Peripheral Neuropathy in Newly Diagnosed Patients with Multiple Myeloma Receiving Bortezomib Induction

Laura Sun, Kathryn T. Maples, Kevin H. Hall, Yuan Liu, Yichun Cao, Nisha S. Joseph, Craig C Hofmeister, Jonathan L. Kaufman, Madhav Dhodapkar, Ajay K. Nooka, Sagar Lonial, R Donald Harvey

Blood (2022) 140 (Supplement 1): 7131–7132.

https://doi.org/10.1182/blood-2022-159189

Published: 2022

Journal Articles

Genomic Sequencing of Paired Bone Marrow and Focal Lesion Biopsies of Newly Diagnosed Multiple Myeloma Patients before and after Induction Therapy

Blood (2022) 140 (Supplement 1): 7086–7087.

https://doi.org/10.1182/blood-2022-168109

Published: 2022

Journal Articles

Enhanced Global Disease Assessment with Advanced Imaging and Targeted Myeloma Lesion Biopsy Highlights Spatial Heterogeneity and Detects Residual Disease in Multiple Myeloma

Blood (2022) 140 (Supplement 1): 7308–7310.

https://doi.org/10.1182/blood-2022-166325

Published: 2022

Journal Articles

SWOG S0120 Observational Trial for MGUS and Asymptomatic Multiple Myeloma (AMM): Imaging Predictors of Progression for Patients Treated At UAMS,

Christoph Heuck, MD, Rachael Sexton, Madhav Dhodapkar, MD, MBBS, Qing Zhang, PhD, Saad Usmani, MD, FACP, Bijay Nair, MD, Frits van Rhee, MD, PhD, Antje Hoering, PhD, John Crowley, PhD, John D Shaughnessy, Jr., PhD, Robert Z. Orlowski, MD, PhD, Bart Barlogie, MD, PhD

Blood (2011) 118 (21): 3955.

https://doi.org/10.1182/blood.V118.21.3955.3955

Published: 2011

Journal Articles

Predicting Disease Progression to Multiple Myeloma (MM) From MGUS/SMM In SWOG-0120 Observational Trial

Madhav Dhodapkar, MD, MBBS, John Shaughnessy, Jr, PhD, Antje Hoering, PhD, Bijay Nair, MD, MPH, Vanessa Bolejack, Frits van Rhee, MD, PhD, John Crowley, PhD, Bart Barlogie, MD, PhD

Blood (2010) 116 (21): 1932.

https://doi.org/10.1182/blood.V116.21.1932.1932

Published: 2010

Journal Articles

First thalidomide clinical trial in multiple myeloma: a decade

Frits van Rhee, Madhav Dhodapkar, John D. Shaughnessy, Jr, Elias Anaissie, David Siegel, Antje Hoering, Jerome Zeldis, Bonnie Jenkins, Seema Singhal, Jayesh Mehta, John Crowley, Sundar Jagannath, Bart Barlogie

Blood (2008) 112 (4): 1035–1038.

https://doi.org/10.1182/blood-2008-02-140954

Published: 2008

Journal Articles

Dendritic cells are specialized accessory cells along with TGF-β for the differentiation of Foxp3 + CD4 + regulatory T cells from peripheral Foxp3 − precursors

Sayuri Yamazaki, Anthony J. Bonito, Radek Spisek, Madhav Dhodapkar, Kayo Inaba, Ralph M. Steinman

Blood (2007) 110 (13): 4293–4302.

https://doi.org/10.1182/blood-2007-05-088831

Published: 2007

Includes: Supplemental data

Journal Articles

Gene Expression Profiles for Prognosis in MGUS, Coupled with Signatures of Oncogenic Pathway Deregulation Provide a Novel Approach for Selection of Molecular Targets in Multiple Myeloma.

Ariel Anguiano, MD, Chaitanya Acharya, Kelly Salter, Daniel McCluskey, Christina Gasperetto, MD, Fenghuang Zhan, MD, Madhav Dhodapkar, PhD, Joseph Nevins, PhD, Bart Barlogie, MD, John D. Shaughnessy, Jr., PhD, Anil Potti, MD

Blood (2007) 110 (11): 655.

https://doi.org/10.1182/blood.V110.11.655.655

Published: 2007

Journal Articles

International Prognostic Scoring System (IPSS) for Waldenström’s Macroglobulinemia (WM).

Pierre Morel, Alain Duhamel, Paolo Gobbi, Meletios Dimopoulos, Madhav Dhodapkar, Jason McCoy, Enrique Ocio, Ramon Garcia-Sanz, Steven Treon, Veronique Leblond, Robert Kyle, Bart Barlogie, Giampaolo Merlini

Blood (2006) 108 (11): 127.

https://doi.org/10.1182/blood.V108.11.127.127

Published: 2006

Journal Articles

A Gene Expression Signature of Benign Monoclonal Gammopathy Evident in Multiple Myeloma Is Linked to Good Prognosis.

Fenghuang Zhan, Bart Barlogie, Varant Arzoumanian, Yongsheng Huang, Klaus Hollmig, Mauricio Pineda-Roman, Guido Tricot, Frits van Rhee, Maurizio Zangari, Madhav Dhodapkar, John D. Shaughnessy, Jr.

Blood (2006) 108 (11): 3393.

https://doi.org/10.1182/blood.V108.11.3393.3393

Published: 2006

Journal Articles

Gene-expression signature of benign monoclonal gammopathy evident in multiple myeloma is linked to good prognosis

Fenghuang Zhan, Bart Barlogie, Varant Arzoumanian, Yongsheng Huang, David R. Williams, Klaus Hollmig, Mauricio Pineda-Roman, Guido Tricot, Frits van Rhee, Maurizio Zangari, Madhav Dhodapkar, John D. Shaughnessy, Jr

Blood (2006) 109 (4): 1692–1700.

https://doi.org/10.1182/blood-2006-07-037077

Published: 2006

Includes: Supplemental data

Journal Articles

The Serum Free Light Chain Ratio after One or Two Cycles of Treatment Is Highly Predictive of the Magnitude of Final Response in Patients Undergoing Initial Treatment for Multiple Myeloma.

Hani Hassoun, MD, Lilian Reich, MD, Virginia M. Klimek, MD, Madhav Dhodapkar, MD, Adam Cohen, MD, Tarun Kewalramani, MD, Elyn R. Riedel, MA, Cyrus V. Hedvat, MD, Julie Teruya-Feldstein, MD, Daniel A. Filippa, MD, Martin Fleisher, PhD, Stephen D. Nimer, MD, Raymond L. Comenzo, MD

Blood (2005) 106 (11): 3481.

https://doi.org/10.1182/blood.V106.11.3481.3481

Published: 2005

Journal Articles

Differential Antigenic Targets of Anti-Tumor Immune Response and Selective Immunity to Stem Cell Associated Group B SOX Proteins in Preneoplastic Versus Malignant Gammopathy.

Radek Spisek, Lyn-Chi Chen, Matthew Scanlan, Andrew Simpson, Gerd Ritter, Erik Rasmussen, Jason McCoy, Anne Murray, Joseph Krasovsky, Brian Durie, John Crowley, Amitabha Mazumder, Sundar Jagannath, Bart Barlogie, Ali Gure, Madhav Dhodapkar

Blood (2005) 106 (11): 5116.

https://doi.org/10.1182/blood.V106.11.5116.5116

Published: 2005

Journal Articles

Risk-Adapted Dosing of Melphalan for Systemic AL Amyloidosis (AL) Lowers Treatment-Related Mortality: Early Death but Not Post-3 Month Survival Is Linked to Cardiac Involvement.

Raymond L. Comenzo, MD, Ping Zhou, MD, PhD, Hani Hassoun, MD, Tarun Kewalramani, MD, Virginia Klimek, MD, Adam D. Cohen, MD, Susane K. Ferrand, MD, Madhav Dhodapkar, MD, Julie Teruya-Feldstein, MD, Martin Fleisher, PhD, Stephen D. Nimer, MD

Blood (2005) 106 (11): 1156.

https://doi.org/10.1182/blood.V106.11.1156.1156

Published: 2005

NARROW

Tumor-Immune Architecture and the Regulation of Antigen-Specific T-Cell Infiltration in Multiple Myeloma and Premalignant Plasma Cell Disorders

KarMMa-2 Cohort 2a: Efficacy and Safety of Idecabtagene Vicleucel in Clinical High-Risk Multiple Myeloma Patients with Early Relapse after Frontline Autologous Stem Cell Transplantation

KarMMa-2 Cohort 2c: Efficacy and Safety of Idecabtagene Vicleucel in Patients with Clinical High-Risk Multiple Myeloma Due to Inadequate Response to Frontline Autologous Stem Cell Transplantation

Phase 1 Trial of AUC-Targeted Melphalan in Myeloma Patients Undergoing Autologous Transplant (The MyMel Study)

A Phase 2 Evaluation of Daratumumab-Based Induction Therapy in Multiple Myeloma Patients with Severe Renal Insufficiency

Updated Safety and Efficacy of REGN5458, a BCMAxCD3 Bispecific Antibody, Treatment for Relapsed/Refractory Multiple Myeloma: A Phase 1/2 First-in-Human Study

African American Race As a Risk Factor for Developing Peripheral Neuropathy in Newly Diagnosed Patients with Multiple Myeloma Receiving Bortezomib Induction

Genomic Sequencing of Paired Bone Marrow and Focal Lesion Biopsies of Newly Diagnosed Multiple Myeloma Patients before and after Induction Therapy

Enhanced Global Disease Assessment with Advanced Imaging and Targeted Myeloma Lesion Biopsy Highlights Spatial Heterogeneity and Detects Residual Disease in Multiple Myeloma

SWOG S0120 Observational Trial for MGUS and Asymptomatic Multiple Myeloma (AMM): Imaging Predictors of Progression for Patients Treated At UAMS,

Predicting Disease Progression to Multiple Myeloma (MM) From MGUS/SMM In SWOG-0120 Observational Trial

First thalidomide clinical trial in multiple myeloma: a decade

Dendritic cells are specialized accessory cells along with TGF-β for the differentiation of Foxp3 + CD4 + regulatory T cells from peripheral Foxp3 − precursors

Gene Expression Profiles for Prognosis in MGUS, Coupled with Signatures of Oncogenic Pathway Deregulation Provide a Novel Approach for Selection of Molecular Targets in Multiple Myeloma.

International Prognostic Scoring System (IPSS) for Waldenström’s Macroglobulinemia (WM).

A Gene Expression Signature of Benign Monoclonal Gammopathy Evident in Multiple Myeloma Is Linked to Good Prognosis.

Gene-expression signature of benign monoclonal gammopathy evident in multiple myeloma is linked to good prognosis

The Serum Free Light Chain Ratio after One or Two Cycles of Treatment Is Highly Predictive of the Magnitude of Final Response in Patients Undergoing Initial Treatment for Multiple Myeloma.

Differential Antigenic Targets of Anti-Tumor Immune Response and Selective Immunity to Stem Cell Associated Group B SOX Proteins in Preneoplastic Versus Malignant Gammopathy.

Risk-Adapted Dosing of Melphalan for Systemic AL Amyloidosis (AL) Lowers Treatment-Related Mortality: Early Death but Not Post-3 Month Survival Is Linked to Cardiac Involvement.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only